

## PRODUCT MONOGRAPH

Pr **SIGNIFOR**<sup>®</sup>

(Pasireotide Injection)

0.3 mg/mL, 0.6 mg/mL and 0.9 mg/mL  
pasireotide (as pasireotide diaspertate)

SYNTHETIC PASIREOTIDE ANALOGUE OF SOMATOSTATIN

Novartis Pharmaceuticals Canada Inc.  
385, Boulevard Bouchard  
Dorval, Quebec, H9S 1A9

Date of Preparation:  
September 23, 2013

Control No: 193942

Date of revision:  
March 21, 2017

Pr SIGNIFOR is a registered trademark

## Table of Contents

|   |           |
|---|-----------|
| <b>PART I: HEALTH PROFESSIONAL INFORMATION.....</b> | <b>3</b>  |
| SUMMARY PRODUCT INFORMATION .....                   | 3         |
| INDICATIONS AND CLINICAL USE.....                   | 3         |
| CONTRAINDICATIONS .....                             | 3         |
| WARNINGS AND PRECAUTIONS.....                       | 4         |
| ADVERSE REACTIONS.....                              | 10        |
| DRUG INTERACTIONS .....                             | 15        |
| DOSAGE AND ADMINISTRATION .....                     | 18        |
| OVERDOSAGE .....                                    | 19        |
| ACTION AND CLINICAL PHARMACOLOGY .....              | 19        |
| STORAGE AND STABILITY.....                          | 26        |
| SPECIAL HANDLING INSTRUCTIONS .....                 | 26        |
| DOSAGE FORMS, COMPOSITION AND PACKAGING .....       | 26        |
| <br>  |           |
| <b>PART II: SCIENTIFIC INFORMATION .....</b>        | <b>27</b> |
| PHARMACEUTICAL INFORMATION.....                     | 27        |
| DETAILED PHARMACOLOGY .....                         | 30        |
| TOXICOLOGY .....                                    | 31        |
| REFERENCES .....                                    | 34        |
| <br>  |           |
| <b>PART III: CONSUMER INFORMATION.....</b>          | <b>35</b> |

Pr **SIGNIFOR®**

(Pasireotide Injection)

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

| <b>Route of Administration</b> | <b>Dosage Form / Strength</b>   | <b>Clinically Relevant Nonmedicinal Ingredients</b>  |
|--------------------------------|---|--|
| subcutaneous (s.c.)            | Each ampoule of 1 mL contains:<br>SIGNIFOR 0.3mg - 0.3 mg pasireotide (as diaspartate).<br>SIGNIFOR 0.6mg - 0.6 mg pasireotide (as diaspartate).<br>SIGNIFOR 0.9mg - 0.9 mg pasireotide (as diaspartate). | Mannitol, sodium hydroxide, tartaric acid, water for injections<br><br><i>For a complete listing see</i><br><b>DOSAGE FORMS, COMPOSITION AND PACKAGING</b> |

**INDICATIONS AND CLINICAL USE**

SIGNIFOR (pasireotide) is indicated for:

- Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed, as long as clinical benefit or normalization of UFC (or >50% decrease in UFC) are derived.

SIGNIFOR should be prescribed and supervised by a qualified physician. To receive SIGNIFOR, patient must be enrolled in the Access Program for SIGNIFOR.

**Geriatrics (≥ 65 years of age):**

Data on Cushing's disease patients older than 65 years are too limited to determine whether they respond differently from younger subjects.

**Pediatrics (< 18 years of age):**

SIGNIFOR should not be used in pediatric patients. There are no clinical data available in patients under 18 years of age.

**CONTRAINDICATIONS**

SIGNIFOR (pasireotide) is contraindicated in:

- Patients with moderate or severe hepatic impairment (Child-Pugh B or C).
- Patients with uncontrolled diabetes (≥8% HbA1c), despite receiving anti-diabetic

therapy.

- Patients with the following cardiovascular conditions:
  - NYHA Class III to IV heart failure
  - Cardiogenic shock
  - Second or third degree atrioventricular (AV) block, sinoatrial block, or sick sinus syndrome (unless patient has a functioning pacemaker)
  - Severe bradycardia
  - Congenital long QT syndrome or baseline QTc interval  $\geq 500$  ms
- Patients who are hypersensitive to pasireotide or to any ingredient in the formulation or component of the container. For a complete listing, see **DOSAGE FORMS, COMPOSITION AND PACKAGING**.

## WARNINGS AND PRECAUTIONS

### Serious Warnings and Precautions

#### RISK OF HEPATOTOXICITY:

- Elevations in liver aminotransferases are commonly observed with pasireotide (see **CONTRAINDICATIONS; WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests; ADVERSE REACTIONS**).
- 4 cases (3 healthy volunteers and 1 Cushing's disease patient) that met the biochemical criteria for Hy's Law have been reported in Clinical Trials (see **WARNINGS AND PRECAUTIONS; ADVERSE REACTIONS**).

#### RISK OF CARDIOVASCULAR (CV) ADVERSE EVENTS (AEs):

- Pasireotide can cause bradycardia and atrioventricular block (see **CONTRAINDICATIONS; WARNINGS AND PRECAUTIONS; ADVERSE REACTIONS; ACTION AND CLINICAL PHARMACOLOGY**).
- Pasireotide has been shown to prolong the QTc interval on the ECG (see **CONTRAINDICATIONS; WARNINGS AND PRECAUTIONS; ACTION AND CLINICAL PHARMACOLOGY**).

#### RISK OF HYPERGLYCEMIA:

- Frequent, significant alterations in blood glucose levels have been seen in healthy volunteers and Cushing's disease patients treated with pasireotide (see **ADVERSE REACTIONS; CLINICAL TRIALS**).

### Cardiovascular

**Bradycardia and PR Interval Prolongation:** Pasireotide causes a decrease in heart rate and PR interval prolongation (see **ACTION AND CLINICAL PHARMACOLOGY - Cardiac Electrophysiology**). Careful monitoring of patients with a low heart rate at baseline (< 60 beats per minute), a history of syncope or arrhythmia, ischemic heart disease, or congestive heart failure is recommended. Concomitant medications that decrease heart rate, prolong the PR interval and/or prolong the QTc interval should be avoided to the extent possible during

treatment with SIGNIFOR (see **DRUG INTERACTIONS**).

**QTc Prolongation:** Pasireotide is associated with QTc prolongation (see **ADVERSE REACTIONS; ACTION AND CLINICAL PHARMACOLOGY - Cardiac Electrophysiology**). SIGNIFOR should not be used in patients with congenital long QT syndrome (see **CONTRAINDICATIONS**). SIGNIFOR should be used with caution in patients who are at significant risk of developing prolongation of QT, including, but not limited to, the following:

- QTc prolongation at baseline or a family history of sudden cardiac death at <50 years
- with uncontrolled or significant cardiac disease including recent myocardial infarction, congestive heart failure, left ventricular hypertrophy, cardiomyopathy, unstable angina or clinically significant bradycardia, a history of significant arrhythmias, or any other risk factors for torsades de pointes
- taking other substances that are known to lead to QT prolongation, including anti-arrhythmic medicinal products (see **DRUG INTERACTIONS**).
- diabetes mellitus, especially with autonomic neuropathy
- with hypokalemia, hypocalcaemia and/or hypomagnesaemia (see **WARNINGS AND PRECAUTIONS - Renal**)

Female gender and age 65 years or older are risk factors for torsade de pointes.

Monitoring for an effect on the QTc interval is advisable. A baseline ECG is recommended prior to initiating therapy with SIGNIFOR and as clinically indicated.

Concomitant medications that cause QTc prolongation should be avoided during treatment with SIGNIFOR (see **DRUG INTERACTIONS**). When drugs that prolong the QTc interval are prescribed, healthcare professionals should consider the nature and implications of the ECG changes, underlying diseases and disorders that are considered to represent risk factors, demonstrated and predicted drug-drug interactions, symptoms suggestive of arrhythmia, risk management strategies, and other information relevant to the use of the drug in consultation with the patient.

## **Endocrine and Metabolism**

### **Hypocortisolism**

Treatment with SIGNIFOR leads to a rapid suppression of adrenocorticotrophic hormone (ACTH) secretion in Cushing's disease patients which may lead to a decrease in circulating levels of cortisol and potentially to transient hypocortisolism/hypoadrenalism. Cases of hypocortisolism have been reported in the Phase III study in Cushing's disease patients (see **ADVERSE REACTIONS**), generally within the first two months of treatment. Except for one case in which treatment was discontinued, all other cases were manageable by reducing the dose of SIGNIFOR and/or adding low-dose, short-term glucocorticoid therapy.

It is therefore necessary to monitor and instruct patients on the signs and symptoms associated with hypocortisolism (e.g. weakness, fatigue, anorexia, nausea, vomiting, hypotension, hyponatraemia or hypoglycaemia). In case of documented hypocortisolism, temporary

exogenous steroid (glucocorticoid) replacement therapy and/or dose reduction or interruption of treatment with SIGNIFOR may be necessary.

### **Glucose Metabolism**

In the pivotal trial, a mean increase in HbA1c of approximately 1.5% relative to baseline occurred early during treatment and continued throughout the duration of the trial. Of patients with normal ( $\leq 6\%$ ) HbA1c at baseline, 62% became either pre-diabetic or diabetic by month 6. The effect of SIGNIFOR on hyperglycemia was both dose-dependent and higher in patients with pre-diabetic conditions or established, controlled diabetes mellitus at baseline. During the trial, the use of antihyperglycemic agents increased from 6.2% to 22.8% for insulin, from 0.6% to 9.3% for glinides, from 1.9% to 21.6% for sulphonamides, and from 15.4% to 43% for metformin. Patients with uncontrolled diabetes ( $\geq 8\%$  HbA1c) were excluded from the trial (see **CONTRAINDICATIONS**).

Once SIGNIFOR treatment has been initiated, monitoring of blood glucose should be done weekly for the first two to three months and at least once monthly after a stable dose of SIGNIFOR has been established. Weekly monitoring should be resumed for two to three months after a dose increase (see **WARNINGS AND PRECAUTIONS – Monitoring and Laboratory Tests**). If uncontrolled hyperglycemia persists, despite appropriate medical management, the dose of SIGNIFOR should be reduced or discontinued.

SIGNIFOR should not be administered to Cushing's disease patients with poor glycemic control (as defined by HbA1c values  $\geq 8\%$  while receiving anti-diabetic therapy) as they may be at a higher risk of developing severe hyperglycemia and associated complications (e.g. ketoacidosis) (see **CONTRAINDICATIONS**).

### **Pituitary hormones**

Cushing's disease patients with persistent or recurrent disease might present with deficiency of one or more pituitary hormones. As the pharmacological activity of pasireotide mimics that of somatostatin, inhibition of pituitary hormones, other than ACTH, cannot be ruled out. Therefore, monitoring of pituitary function (e.g. TSH/free T<sub>4</sub>, GH/IGF-1) prior to initiation of therapy with SIGNIFOR and periodically during treatment should be conducted as clinically appropriate.

### **Hematologic**

The safety of the combination of SIGNIFOR with anticoagulants has not been established. Patients should be monitored regularly for alterations in their coagulation parameters and the anticoagulant dose should be adjusted accordingly (see **DRUG INTERACTIONS – Drug-Drug Interactions**).

### **Hepatic/Biliary/Pancreatic**

#### **Hepatic**

In the pivotal trial, the proportions of patients with shifts in hepatobiliary biochemistry parameters from normal to high were: 30.8% for GGT, 24.4% for AST, 32.1% for ALT and 3.2% for total bilirubin. Eight Cushing's patients (5.1%) had elevations of ALT or AST  $> 3x$  upper limit of normal (ULN). Concurrent elevations of ALT or AST  $> 3x$  ULN and total bilirubin

$\geq 2$ xULN, meeting the definition of Hy's Law, were reported within 4-10 days of initiating treatment with SIGNIFOR in 3 healthy volunteers and one Cushing's patient (see **ADVERSE REACTIONS**). The cases had an early onset and the patient with Cushing's disease developed jaundice. Liver test elevations resolved upon discontinuation of SIGNIFOR.

Monitoring of liver function is recommended prior to treatment with pasireotide, weekly for one month, every two weeks for 3 months and every 3 months on treatment thereafter. Close monitoring should be resumed with any dose increase (see **WARNINGS AND PRECAUTIONS – Monitoring and Laboratory Tests**).

Patients who develop increased transaminase levels should be monitored closely.

If elevations of ALT are above 5 times the ULN or if ALT or AST elevations greater than 3 x ULN occur concurrently with bilirubin elevations greater than 2 x ULN, or if the patient develops jaundice or other signs suggestive of clinically significant liver impairment, discontinue SIGNIFOR treatment and investigate for probable cause of the findings. If elevations of ALT exceed 3 times the ULN but are below 5 times the ULN, repeat the test within 48 hours. If the values are confirmed below 5 times the upper limit of normal, keep on monitoring every 48 hours. If the values rise above five times the ULN, discontinue SIGNIFOR treatment. Following discontinuation of treatment with pasireotide, patients should be monitored until resolution. Treatment should not be restarted. Concomitant medications with hepatotoxic potential should be used with caution during treatment with SIGNIFOR.

### **Pancreatic**

Elevations in lipase and amylase were observed in patients receiving pasireotide in clinical studies. Twenty-one (13%) patients reported pancreatitis-related adverse events. The elevations were reversible while continuing treatment (see **WARNINGS AND PRECAUTIONS - Monitoring and Laboratory Tests**). Elevations in lipase and amylase were more pronounced in patients with renal impairment (see **WARNINGS AND PRECAUTIONS – Renal**).

### **Biliary**

Cholelithiasis has been frequently reported in clinical studies with pasireotide (see **ADVERSE REACTIONS**). Ultrasonic examination of the gallbladder before, and at 6- to 12-month intervals during SIGNIFOR therapy is therefore recommended. The presence of gallstones in SIGNIFOR-treated patients is largely asymptomatic; stones should be managed according to clinical practice.

### **Renal**

Hypokalemia, hypocalcaemia or hypomagnesaemia must be corrected prior to SIGNIFOR administration and electrolytes should be monitored periodically during therapy (see **WARNINGS AND PRECAUTIONS - Monitoring and Laboratory Tests**). Caution should be observed in patients in conditions that can lead to electrolyte imbalances (e.g., diarrhea, use of diuretics).

The use of SIGNIFOR with drugs that can disrupt electrolyte levels should be avoided. Such drugs include, but are not limited to, the following: loop, thiazide, and related diuretics; laxatives and enemas; amphotericin B; high dose corticosteroids.

In a clinical study of single dose pasireotide s.c, 900 µg, grade 3 and grade 4 increases in amylase, lipase and uric acid and grade 3 decreases in hemoglobin were observed in subjects with severe renal impairment and ESRD. SIGNIFOR should be used with caution in patients with severe renal impairment and ESRD (see **WARNINGS AND PRECAUTIONS – Monitoring and Laboratory Tests, DOSAGE AND ADMINISTRATION, ACTION AND CLINICAL PHARMACOLOGY**).

### **Sexual Function/Reproduction**

A reduction or normalization of serum cortisol levels in female patients with Cushing's disease treated with SIGNIFOR could potentially restore fertility. Female patients of childbearing potential should be advised to use adequate contraception during treatment with SIGNIFOR (see **WARNINGS AND PRECAUTIONS – Special Populations**). Studies in rats with pasireotide via the s.c. route have shown effects on female reproductive parameters (see **TOXICOLOGY**). The clinical relevance of these effects in humans is unknown.

### **Special Populations**

**Women of child-bearing potential and contraceptive measures:** Animal studies have shown pasireotide to be harmful to the developing fetus. Women of child-bearing potential should be instructed to use effective contraception during treatment with SIGNIFOR, and also advised that treatment with SIGNIFOR could potentially restore fertility.

**Pregnant Women:** SIGNIFOR should not be used during pregnancy. There are no adequate and well-controlled studies in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is not known (see **TOXICOLOGY**).

**Nursing Women:** SIGNIFOR should not be used in nursing women. It is not known whether pasireotide is excreted in human milk. Available data in rats with pasireotide via the s.c. route have shown excretion of pasireotide in milk (see **DETAILED PHARMACOLOGY, Nonclinical Pharmacokinetics**). A risk to the breastfed child cannot be excluded.

**Pediatrics (< 18 years of age):** SIGNIFOR should not be used in pediatric patients. There are no clinical data available in patients under 18 years of age.

**Geriatrics (≥ 65 years of age):** There are limited data on the use of SIGNIFOR in patient 65 years and older. Clinical studies of SIGNIFOR did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

**Renal Impairment:** No dose adjustment is required in patients with impaired renal function. SIGNIFOR should be used with caution in patients with severe renal impairment and ESRD (see **WARNINGS AND PRECAUTIONS – Renal, WARNINGS AND PRECAUTIONS-**



**Monitoring and laboratory tests, DOSAGE AND ADMINISTRATION, ACTION AND CLINICAL PHARMACOLOGY).**

**Hepatic Impairment:** SIGNIFOR is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C).

**Monitoring and Laboratory Tests**

Patients should be evaluated for treatment response (Normalization or >50% decrease in Urinary Free Cortisol [UFC] levels and/or improvement in signs or symptoms of the disease) and should continue receiving therapy with SIGNIFOR as long as benefit is derived. Maximum urinary free cortisol reduction is typically seen by two months of treatment. Patients who do not experience clinical benefit from therapy with SIGNIFOR should be considered for discontinuation as studies have shown that non-responders do not usually improve after this time period.

**Hypocortisolism:** It is necessary to monitor and instruct patients on the signs and symptoms associated with hypocortisolism (e.g. weakness, fatigue, anorexia, nausea, vomiting, hypotension, hyponatraemia or hypoglycaemia).

**Liver Chemistry:** Monitoring of liver chemistry is recommended prior to treatment with SIGNIFOR (see **CONTRAINDICATIONS**). Upon treatment initiation, liver chemistry should be monitored weekly for one month, every two weeks for 3 months and every 3 months thereafter. Four cases meeting the biochemical criteria for Hy's law have been reported within 4-10 days of initiating treatment with SIGNIFOR. Close monitoring of liver function should be resumed with any dose increase (see **WARNINGS AND PRECAUTIONS - Hepatic/Biliary/Pancreatic**).

**Electrocardiograms:** A baseline ECG is recommended prior to initiating therapy with SIGNIFOR (see **CONTRAINDICATIONS**), followed by periodic ECG monitoring during treatment, as clinically indicated, for effects on the QTc interval, heart rate and AV conduction (see **WARNINGS AND PRECAUTIONS - Cardiovascular**).

**Electrolytes:** Hypokalemia, hypocalcaemia or hypomagnesaemia must be corrected prior to SIGNIFOR administration and electrolytes should be monitored periodically during therapy.

**Glycemic Status:** Glycemic status (fasting plasma glucose/hemoglobin A1c [FPG/HbA1c]) should be assessed prior to starting treatment with pasireotide. Monitoring of blood glucose should be done weekly for the first two to three months and at least once monthly after a stable dose of SIGNIFOR has been established. Weekly monitoring of blood glucose should be resumed for two to three months after a dose increase (see **WARNINGS AND PRECAUTIONS – Endocrine and Metabolism, Glucose Metabolism**).

**Lipase:** Lipase should be monitored prior to onset of therapy with SIGNIFOR and periodically during treatment, especially in patients with severe renal impairment and ESRD.

**Gallbladder Ultrasound:** Ultrasonic examination of the gallbladder before, and at 6- to 12-month intervals during SIGNIFOR therapy is recommended (see **WARNINGS AND**

## **PRECAUTIONS - Hepatic/Biliary/Pancreatic, Gallbladder and related events).**

**Pituitary Function:** Monitoring of pituitary function (e.g. TSH/free T<sub>4</sub>, GH/IGF-1) prior to initiation of therapy with SIGNIFOR and periodically during treatment should be conducted as clinically appropriate.

**Cyclosporine:** Cyclosporine level should be monitored to maintain therapeutic levels (see **DRUG INTERACTIONS – Drug-Drug Interactions**).

**Hematologic:** Monitoring of coagulation parameters should be performed in patients treated concomitantly with SIGNIFOR and anticoagulant drugs (see **WARNINGS AND PRECAUTIONS – Hematologic and DRUG INTERACTIONS – Drug-Drug Interactions**).

## **ADVERSE REACTIONS**

### **Adverse Drug Reaction Overview**

A total of 201 Cushing's disease patients received SIGNIFOR in Phase II (N=39) and Phase III (N=162) studies.

In the pivotal study, adverse drug reactions (ADRs) that led to study discontinuation were reported in 28 (17.3%) patients. The most common were hyperglycemia-related [10 (6%)], gamma-glutamyltransferase increase [5 (3.1%)], diabetes mellitus [4 (2.5%)] and diarrhea [3 (1.9%)]. The most common adverse drug reactions requiring clinical intervention (dose adjustment/interruption or requiring additional therapy) were metabolism/nutrition adverse reactions related to hyperglycemia, GI-related (abdominal pain, diarrhea, nausea), adrenal insufficiency and cholelithiasis.

The most common ADRs (incidence  $\geq 10\%$ ) were diarrhea, nausea, abdominal pain, cholelithiasis, hyperglycemia, diabetes mellitus, fatigue and glycosylated hemoglobin increase. Serious ADRs were reported in 11.7% of patients. Serious ADRs ( $\geq 1\%$  incidence in all patients) included cholelithiasis, diabetes mellitus and hyperglycemia which were reported in 4 (2.5%) patients, each, and adrenal insufficiency reported in 2 (1.2%) patients.

### **Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

Adverse drug reactions reported, with an overall frequency higher than or equal to 1% are presented in Table 1 by randomised dose group.

**Table 1 - Adverse drug reactions with an overall frequency of greater than or equal to 1% in the Phase III study in Cushing's disease patients**

| <b>Primary system organ class</b>                           | <b>Pasireotide 600 ug bid</b> | <b>Pasireotide 900 ug bid</b> | <b>Overall</b> |
|---|-------------------------------|-------------------------------|----------------|
| <b>Preferred term</b>                                       | <b>N=82</b>                   | <b>N=80</b>                   | <b>N=162</b>   |
|   | <b>n (%)</b>                  | <b>n (%)</b>                  | <b>n (%)</b>   |
| <b>Cardiac disorders</b>                                    |                               |                               |                |
| Sinus bradycardia   | 6(7.3)                        | 1(1.3)                        | 7(4.3)         |
| <b>Ear and labyrinth disorders</b>                          |                               |                               |                |
| Vertigo   | 1(1.2)                        | 3(3.8)                        | 4(2.5)         |
| <b>Endocrine disorders</b>                                  |                               |                               |                |
| Adrenal insufficiency                                       | 4(4.9)                        | 5(6.3)                        | 9(5.6)         |
| <b>Eye disorders</b>  |                               |                               |                |
| Vision blurred  | 0(0.0)                        | 2(2.5)                        | 2(1.2)         |
| <b>Gastrointestinal disorders</b>                           |                               |                               |                |
| Diarrhea  | 46(56.1)                      | 43(53.8)                      | 89(54.9)       |
| Nausea  | 33(40.2)                      | 43(53.8)                      | 76(46.9)       |
| Abdominal pain  | 14(17.1)                      | 19(23.8)                      | 33(20.4)       |
| Vomiting  | 2(2.4)                        | 8(10.0)                       | 10(6.2)        |
| Abdominal pain upper  | 6(7.3)                        | 3(3.8)                        | 9(5.6)         |
| Flatulence  | 4(4.9)                        | 2(2.5)                        | 6(3.7)         |
| Abdominal distension  | 2(2.4)                        | 3(3.8)                        | 5(3.1)         |
| Dry mouth   | 4(4.9)                        | 1(1.3)                        | 5(3.1)         |
| Frequent bowel movements                                    | 3(3.7)                        | 2(2.5)                        | 5(3.1)         |
| Abdominal discomfort  | 2(2.4)                        | 1(1.3)                        | 3(1.9)         |
| Constipation  | 2(2.4)                        | 1(1.3)                        | 3(1.9)         |
| Dyspepsia   | 0(0.0)                        | 3(3.8)                        | 3(1.9)         |
| <b>General disorders and administration site conditions</b> |                               |                               |                |
| Injection site reaction*                                    | 13(15.9)                      | 13(16.3)                      | 26(16.0)       |
| Fatigue   | 7(8.5)                        | 12(15.0)                      | 19(11.7)       |
| Asthenia  | 6(7.3)                        | 1(1.3)                        | 7(4.3)         |
| Malaise   | 2(2.4)                        | 3(3.8)                        | 5(3.1)         |
| Microlithiasis  | 1(1.2)                        | 1(1.3)                        | 2(1.2)         |
| <b>Hepatobiliary disorders</b>                              |                               |                               |                |
| Cholelithiasis  | 25(30.5)                      | 23(28.8)                      | 48(29.6)       |
| Cholecystitis   | 3(3.7)                        | 1(1.3)                        | 4(2.5)         |
| Cholestasis   | 2(2.4)                        | 2(2.5)                        | 4(2.5)         |
| Hepatic steatosis   | 1(1.2)                        | 2(2.5)                        | 3(1.9)         |
| Biliary colic   | 0(0.0)                        | 2(2.5)                        | 2(1.2)         |
| <b>Injury, poisoning and procedural complications</b>       |                               |                               |                |
| Procedural nausea   | 1(1.2)                        | 2(2.5)                        | 3(1.9)         |
| Contusion   | 0(0.0)                        | 2(2.5)                        | 2(1.2)         |
| <b>Investigations</b>                                       |                               |                               |                |
| Glycosylated haemoglobin increased                          | 10(12.2)                      | 7(8.8)                        | 17(10.5)       |
| Gamma-glutamyltransferase increased                         | 8(9.8)                        | 7(8.8)                        | 15(9.3)        |
| Alanine aminotransferase increased                          | 9(11.0)                       | 5(6.3)                        | 14(8.6)        |
| Lipase increased  | 7(8.5)                        | 5(6.3)                        | 12(7.4)        |
| Blood glucose increased                                     | 6(7.3)                        | 3(3.8)                        | 9(5.6)         |
| Aspartate aminotransferase increased                        | 5(6.1)                        | 3(3.8)                        | 8(4.9)         |
| Creatinine renal clearance decreased                        | 3(3.7)                        | 3(3.8)                        | 6(3.7)         |
| Electrocardiogram QT prolonged                              | 3(3.7)                        | 3(3.8)                        | 6(3.7)         |

| <b>Primary system organ class</b>                      | <b>Pasireotide 600 ug bid</b> | <b>Pasireotide 900 ug bid</b> | <b>Overall</b> |
|--|-------------------------------|-------------------------------|----------------|
| <b>Preferred term</b>                                  | <b>N=82</b>                   | <b>N=80</b>                   | <b>N=162</b>   |
|  | <b>n (%)</b>                  | <b>n (%)</b>                  | <b>n (%)</b>   |
| Weight decreased                                       | 1(1.2)                        | 5(6.3)                        | 6(3.7)         |
| Blood insulin decreased                                | 1(1.2)                        | 4(5.0)                        | 5(3.1)         |
| Blood creatinine increased                             | 2(2.4)                        | 2(2.5)                        | 4(2.5)         |
| Blood amylase increased                                | 4(4.9)                        | 0(0.0)                        | 4(2.5)         |
| Blood urea increased                                   | 2(2.4)                        | 1(1.3)                        | 3(1.9)         |
| Vitamin B12 decreased                                  | 2(2.4)                        | 1(1.3)                        | 3(1.9)         |
| Activated partial thromboplastin time prolonged        | 1(1.2)                        | 1(1.3)                        | 2(1.2)         |
| Blood alkaline phosphatase increased                   | 2(2.4)                        | 0(0.0)                        | 2(1.2)         |
| Blood cholesterol increased                            | 1(1.2)                        | 1(1.3)                        | 2(1.2)         |
| Cortisol free urine decreased                          | 1(1.2)                        | 1(1.3)                        | 2(1.2)         |
| Low density lipoprotein increased                      | 2(2.4)                        | 0(0.0)                        | 2(1.2)         |
| Prothrombin time prolonged                             | 0(0.0)                        | 2(2.5)                        | 2(1.2)         |
| <b>Metabolism and nutrition disorders</b>              |                               |                               |                |
| Hyperglycaemia   | 31(37.8)                      | 32(40.0)                      | 63(38.9)       |
| Diabetes mellitus                                      | 13(15.9)                      | 16(20.0)                      | 29(17.9)       |
| Type 2 diabetes mellitus                               | 10(12.2)                      | 5(6.3)                        | 15(9.3)        |
| Decreased appetite                                     | 6(7.3)                        | 7(8.8)                        | 13(8.0)        |
| Hypoglycaemia  | 6(7.3)                        | 0(0.0)                        | 6(3.7)         |
| Glucose tolerance impaired                             | 2(2.4)                        | 2(2.5)                        | 4(2.5)         |
| Hypercholesterolaemia                                  | 3(3.7)                        | 0(0.0)                        | 3(1.9)         |
| Hyperlipidaemia  | 1(1.2)                        | 1(1.3)                        | 2(1.2)         |
| Hypertriglyceridaemia                                  | 2(2.4)                        | 0(0.0)                        | 2(1.2)         |
| Polydipsia   | 1(1.2)                        | 1(1.3)                        | 2(1.2)         |
| <b>Musculoskeletal and connective tissue disorders</b> |                               |                               |                |
| Myalgia  | 6(7.3)                        | 1(1.3)                        | 7(4.3)         |
| Arthralgia   | 3(3.7)                        | 1(1.3)                        | 4(2.5)         |
| Muscular weakness                                      | 1(1.2)                        | 1(1.3)                        | 2(1.2)         |
| <b>Nervous system disorders</b>                        |                               |                               |                |
| Headache   | 5(6.1)                        | 7(8.8)                        | 12(7.4)        |
| Dizziness  | 3(3.7)                        | 3(3.8)                        | 6(3.7)         |
| Dysgeusia  | 3(3.7)                        | 3(3.8)                        | 6(3.7)         |
| Somnolence   | 2(2.4)                        | 2(2.5)                        | 4(2.5)         |
| Migraine   | 0(0.0)                        | 2(2.5)                        | 2(1.2)         |
| Syncope  | 1(1.2)                        | 1(1.3)                        | 2(1.2)         |
| Tremor   | 1(1.2)                        | 1(1.3)                        | 2(1.2)         |
| <b>Renal and urinary disorders</b>                     |                               |                               |                |
| Polyuria   | 1(1.2)                        | 1(1.3)                        | 2(1.2)         |
| <b>Skin and subcutaneous tissue disorders</b>          |                               |                               |                |
| Alopecia   | 4(4.9)                        | 5(6.3)                        | 9(5.6)         |
| Skin exfoliation                                       | 5(6.1)                        | 3(3.8)                        | 8(4.9)         |
| Pruritus   | 4(4.9)                        | 4(5.0)                        | 8(4.9)         |
| Dry skin   | 3(3.7)                        | 2(2.5)                        | 5(3.1)         |
| Hyperhidrosis  | 1(1.2)                        | 2(2.5)                        | 3(1.9)         |
| Rash   | 2(2.4)                        | 0(0.0)                        | 2(1.2)         |
| Urticaria  | 0(0.0)                        | 2(2.5)                        | 2(1.2)         |
| Ecchymosis   | 0(0.0)                        | 2(2.5)                        | 2(1.2)         |

| Primary system organ class<br>Preferred term | Pasireotide 600 ug bid | Pasireotide 900 ug bid | Overall        |
|--|------------------------|------------------------|----------------|
|  | N=82<br>n (%)          | N=80<br>n (%)          | N=162<br>n (%) |
| <b>Vascular disorders</b>                    |                        |                        |                |
| Hypotension                                  | 2(2.4)                 | 4(5.0)                 | 6(3.7)         |
| Flushing                                     | 1(1.2)                 | 2(2.5)                 | 3(1.9)         |
| Haematoma                                    | 1(1.2)                 | 1(1.3)                 | 2(1.2)         |
| Hypertension                                 | 1(1.2)                 | 1(1.3)                 | 2(1.2)         |

\*“Injection site reaction” encompasses the following preferred terms: injection site erythema, injection site hematoma, injection site hemorrhage, injection site irritation, injection site pain, injection site pruritus, injection site rash, injection site reaction, injection site swelling, injection site urticaria, immediate post-injection reaction.

### **Less Common Clinical Trial Adverse Drug Reactions (<1%)**

ADRs which occurred with a frequency less than 1% (each ADR below represents 1 patient (0.6%) occurrence) were:

**Blood and lymphatic disorders:** Lymphocytosis, anemia

**Cardiac disorders:** Palpitations, sinus tachycardia, supraventricular tachycardia. A serious event of second degree atrioventricular block was reported in one subject (0.6%).

**Endocrine disorders:** Hypothyroidism, pituitary-dependent Cushing’s syndrome

**Gastrointestinal disorders:** Gastroesophageal reflux disease, haemorrhoids, intestinal polyp, intra-abdominal haemorrhage, retching, salivary hypersecretion, stomatitis, tooth loss

**General disorders and administration site conditions:** Chills, disease progression, irritability, oedema peripheral, thirst

**Hepatobiliary disorders:** Cholecystitis acute, gallbladder polyp, hepatic function abnormal

**Infections and infestations:** Pharyngitis, pharyngotonsillitis, rhinitis, tinea versicolour, tonsillitis

**Injury, poisoning and procedural complications:** Fall, procedural dizziness, procedural headache

**Investigations:** Blood cortisol decreased, blood immunoglobulin E increased, blood insulin increased, blood triglycerides increased, creatinine renal clearance increased, electrocardiogram T wave amplitude decreased, blood corticotrophin increased, hepatic enzyme increased, international normalised ratio increased, liver function test abnormal, thyroxine free decreased, ultrasound biliary tract abnormal

**Metabolism and nutrition disorders:** Dyslipidaemia, fluid retention, food intolerance, lipomatosis, vitamin B complex deficiency

**Musculoskeletal and connective tissue disorders:** Muscle contracture, muscle spasms, musculoskeletal chest pain, pain in extremity

**Nervous system disorders:** Dizziness postural, paresthesia, presyncope, sensory disturbance

**Psychiatric disorders:** Anxiety, mood altered

**Renal and urinary disorders:** Micturition urgency, nocturia, pollakiuria, renal impairment

**Skin and subcutaneous tissue disorders:** Acanthosis nigricans, acne, cutaneous lupus erythematosus, dermatitis acneiform, eczema, erythema rash pruritic

**Vascular disorders:** Hot flush

### **Abnormal Hematologic and Clinical Chemistry Findings**

#### **Liver enzymes**

Elevations in liver enzymes have been reported in healthy subjects and patients receiving pasireotide in clinical studies. Eight patients (5.1%) had elevations of ALT or AST >3xULN. Four cases of concurrent elevations in ALT greater than 3 x ULN and bilirubin greater than 2 x ULN have been observed. All cases of concurrent elevations were identified within ten days of initiation of treatment with SIGNIFOR. Liver function test results returned to baseline values after discontinuation of treatment (see **CONTRAINDICATIONS; WARNINGS AND PRECAUTIONS - Monitoring and Laboratory Tests**).

#### **Pancreatic enzymes**

Based on adverse event reporting in patients receiving pasireotide in clinical studies, elevations were observed in lipase and amylase (7.5% and 2.5%, respectively). All elevations in amylase were low Common Terminology Criteria for Adverse Events v.3.0 (CTC) grade; out of 12 patients who had an increase in lipase, 3 of them had elevations > 2.0 and ≤ 5.0 x ULN (see **WARNINGS AND PRECAUTIONS - Monitoring and Laboratory Tests**).

#### **Glucose metabolism disorders**

Elevated fasting plasma glucose levels was the most frequently reported CTC grade 3 laboratory abnormality (23.2% of patients) in the Phase III study in Cushing's disease patients. Newly occurring or worsening in lab abnormality for FPG was found in 112 out of 155 evaluable patients (72.2%).

Mean HbA1c increases were less pronounced in patients with normal glycemia at study entry in comparison to pre-diabetic patients or diabetic patients (Table 2).

**Table 2** Changes in mean (± range) HbA1c at month 6 according to glycemic status at study entry

| Glycemic status at study entry<br>(n = overall number of patients) | <u>600 ug b.i.d.</u> |         | <u>900 ug b.i.d.</u> |         |
|--|----------------------|---------|----------------------|---------|
|  | Baseline             | Month 6 | Baseline             | Month 6 |

|                                |                   |                    |                   |                    |
|--------------------------------|-------------------|--------------------|-------------------|--------------------|
| Normoglycemic patients (n= 62) | 5.29<br>(4.6-5.6) | 6.50<br>(5.2-7.8)  | 5.22<br>(4.7-5.6) | 6.75<br>(5.4-9.6)  |
| Pre-diabetic patients (n= 38)  | 5.77<br>(5.0-6.3) | 7.45<br>(5.8-11.1) | 5.71<br>(4.7-6.2) | 7.13<br>(5.9-8.0)  |
| Diabetic patients (n= 54)      | 6.50<br>(4.9-8.2) | 7.95<br>(5.4-12.4) | 6.42<br>(5.0-9.1) | 8.30<br>(6.5-10.9) |

Mean fasting plasma glucose (FPG) levels commonly increased within the first month of treatment, and mostly stabilized with the addition of anti-diabetic therapy in subsequent months. Patients with baseline HbA1c  $\geq 7\%$  or who were taking anti-diabetic medications prior to randomization tended to have higher mean changes in fasting plasma glucose and HbA1c relative to other patients. Following SIGNIFOR discontinuation, mean fasting plasma glucose and HbA1c values generally decreased over one month, but remained above baseline values. Long-term follow-up data are not available. Adverse reactions of hyperglycaemia and diabetes mellitus led to study discontinuation in 5 (3.1%) and 4 patients (2.5%), respectively. One case of ketosis and one case of ketoacidosis have been reported during use of SIGNIFOR.

Monitoring of blood glucose levels in patients is required prior to and during treatment with SIGNIFOR (see **CONTRAINDICATIONS; WARNINGS AND PRECAUTIONS**).

## DRUG INTERACTIONS

### Overview

Caution is required when co-administering SIGNIFOR with drugs that are known to have hepatotoxic potential, or with anti-arrhythmic medicines and other drugs that may prolong the QT interval (see **WARNINGS AND PRECAUTIONS**). Medications that may disrupt electrolyte levels should be avoided when using SIGNIFOR.

***In vitro* assessment of drug interactions:** Pasireotide appears to be a substrate of efflux transporter P-gp (P-glycoprotein), but is not an inducer of P-gp. In addition, at therapeutic dose levels, pasireotide is not expected to be:

- A substrate of the efflux transporter BCRP (breast cancer resistance protein) nor of the influx transporters OCT1 (organic cation transporter 1) and OATP (organic anion-transporting polypeptide) 1B1, 1B3 or 2B1;
- An inhibitor of UGT1A1 (uridine diphosphate glucuronosyltransferase 1A1), influx transporter OAT1 or OAT3, OATP 1B1 or 1B3, and OCT1 or OCT2, efflux transporter P-gp, BCRP, MRP2 (multi-drug resistance protein 2) or BSEP (bile salt export pump).

## **Drug-Drug Interactions**

**General:** The lists below of potentially interacting drugs are not comprehensive. Current information sources should be consulted for newly approved drugs that prolong the QTc interval, decrease heart rate, prolong the PR interval, or cause electrolyte disturbances, as well as for older drugs for which these effects have recently been established.

### **Effects of Other Drugs on SIGNIFOR**

**QTc-Prolonging Drugs:** The concomitant use of SIGNIFOR with another QTc-prolonging drug should be avoided (see **WARNINGS AND PRECAUTIONS - Cardiovascular and Monitoring and Laboratory Tests; ADVERSE REACTIONS; ACTIONS AND CLINICAL PHARMACOLOGY - Cardiac Electrophysiology**). Drugs that have been associated with QTc interval prolongation and/or torsade de pointes include, but are not limited to, the examples in the following list. Chemical/pharmacological classes are listed if some, although not necessarily all, class members have been implicated in QTc prolongation and/or torsade de pointes:

- Class IA, III and IC antiarrhythmics
- Antipsychotics
- Antidepressants
- Opioids
- Macrolide antibiotics and analogues
- Quinolone antibiotics
- Antimalarials
- Azole antifungals
- Dopamine receptor antagonists
- Serotonin (5-HT<sub>3</sub>) receptor antagonists
- Tyrosine kinase inhibitors
- Histone deacetylase inhibitors
- Beta-2 adrenoceptor agonists.

**Drugs that Decrease Heart Rate and/or Prolong the PR Interval:** SIGNIFOR results in a decrease in heart rate and an increase in the PR interval (see **WARNINGS AND PRECAUTIONS - Cardiovascular and Monitoring and Laboratory Tests; ADVERSE REACTIONS - Electrocardiography; ACTIONS AND CLINICAL PHARMACOLOGY - Cardiac Electrophysiology**). The concomitant use of SIGNIFOR with other drugs that lower heart rate and/or prolong the PR interval, including, but not limited to, antiarrhythmics, beta blockers, non-dihydropyridine calcium channel blockers, digitalis glycosides, alpha<sub>2</sub>-adrenoceptor agonists, cholinesterase inhibitors, sphingosine-1 phosphate receptor modulators, and HIV protease inhibitors, should be avoided.

**P-gp Substrate Interactions:** Pasireotide appears to be a substrate of efflux transporter P-gp (P-glycoprotein) but is not an inducer of P-gp.

The influence of a P-gp inhibitor on the pharmacokinetics of subcutaneous pasireotide (600 µg, single dose) was tested in a drug-drug interaction study with co-administration of verapamil sustained release formulation (SR) (240 mg, multiple dose) in healthy volunteers. No change in



the rate of pasireotide absorption and elimination or extent of exposure following concomitant administration with verapamil SR was observed. However grade 3 neutropenia, grade 3 lymphopenia, as well as grade 4 lipase and creatine phosphokinase (CPK) increase were observed in some subjects on co-administration. Co-administration of pasireotide with non-dihydropyridine calcium channel blockers such as verapamil should be avoided because of the risk of pharmacodynamic interactions affecting atrioventricular conduction (see **DRUG INTERACTIONS – Drug-Drug Interactions**).

The potential for other strong P-gp inhibitors such as ketoconazole, cyclosporine, clarithromycin, to increase concentrations of pasireotide is unknown.

### **Effect of SIGNIFOR on Other Drugs**

The use of SIGNIFOR with drugs that can disrupt electrolyte levels should be avoided. Such drugs include, but are not limited to, the following: loop, thiazide, and related diuretics; laxatives and enemas; amphotericin B and high dose corticosteroids.

**Anticoagulants:** The safety of the combination of SIGNIFOR with anticoagulants has not been established. Coagulation parameters should be monitored regularly and the anticoagulant dose should be revised accordingly (see **WARNINGS AND PRECAUTIONS**).

**Anti-Diabetics/Insulin:** Dose adjustments (decrease or increase) of insulin and anti-diabetic products may be required when administered concomitantly with pasireotide (see **WARNINGS AND PRECAUTIONS**).

**Bromocriptine:** Coadministration of SIGNIFOR with bromocriptine may increase the blood levels of bromocriptine. Dose reduction of bromocriptine may be necessary.

**Cyclosporine:** Concomitant administration of cyclosporine with SIGNIFOR may decrease the relative bioavailability of cyclosporine. Therefore consider monitoring and dose adjustment of cyclosporine to maintain therapeutic levels.

**Cytochrome P450/3A4 Interactions:** Somatostatin analogs might have an indirect effect in decreasing the metabolic clearance of compounds metabolized by cytochrome P450 (CYP450) enzymes, via suppression of growth hormone secretion. The possibility that pasireotide may exert such an indirect effect cannot be excluded based on available data. Caution should be exercised when administering pasireotide concomitantly with drugs possessing a low therapeutic index and which are metabolized mainly by CYP3A4 (e.g. quinidine).

### **Drug-Food Interactions**

Interactions with food have not been established.

### **Drug-Herb Interactions**

Interactions with herbal products have not been established.

### **Drug-Laboratory Test Interactions**

Interactions with laboratory tests have not been established.

### **Drug-Lifestyle Interactions**

SIGNIFOR has no or negligible influence on the ability to drive and use machines. Patients should be advised to be cautious when driving or using machines if they experience fatigue or headache during treatment with SIGNIFOR.

## **DOSAGE AND ADMINISTRATION**

### **Recommended Dose and Dosage Adjustment**

The recommended initial dose of SIGNIFOR is 0.6 mg by subcutaneous (s.c.) injection twice a day. Patients should be evaluated for treatment response (Normalization or >50% decrease in Urinary Free Cortisol [UFC] levels and/or improvement in signs or symptoms of the disease) and should continue receiving therapy with SIGNIFOR as long as benefit is derived. Maximum UFC reduction is typically seen by two months of treatment. A dose increase to 0.9 mg may be considered based on the response to the treatment, as long as the 0.6 mg dose is well-tolerated by the patient. Patients who do not experience clinical benefit from SIGNIFOR after two months of treatment should be considered for discontinuation. Individualized dose reduction may be considered for patients with a stable response.

Management of suspected adverse reactions may require a dose reduction of SIGNIFOR. The dose may be decreased, either temporarily or permanently, by 0.3 mg decrements. Efficacy should be monitored closely as there are limited data with the use of the 0.3 mg dose.

Prior to the start of SIGNIFOR, patients should have the following baseline evaluations (see **WARNINGS AND PRECAUTIONS**):

- Fasting Plasma Glucose
- Hemoglobin A1c
- Liver tests
- Electrocardiogram
- Gallbladder ultrasound

SIGNIFOR is contraindicated in patients with uncontrolled diabetes mellitus (see **CONTRAINDICATIONS**).

### **Special populations**

#### **Renal impairment:**

No dose adjustment is required in patients with impaired renal function. In a clinical study of single dose pasireotide s.c, 900 µg, grade 3 and grade 4 increases in amylase, lipase and uric acid and grade 3 decreases in hemoglobin were observed in subjects with severe renal impairment and ESRD. SIGNIFOR should be used with caution in patients with severe renal impairment and ESRD (see **WARNINGS AND PRECAUTIONS - Renal, WARNINGS AND PRECAUTIONS – Monitoring and Laboratory Tests, ACTION AND CLINICAL PHARMACOLOGY**).

**Hepatic impairment:**

Dose adjustment is not required in patients with mildly impaired hepatic function (Child-Pugh A). SIGNIFOR is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) (see **CONTRAINDICATIONS; WARNINGS AND PRECAUTIONS**).

**Pediatric patients (< 18 years of age):**

SIGNIFOR should not be used in pediatric Cushing's disease patients (see **INDICATIONS AND CLINICAL USE** and **WARNINGS AND PRECAUTIONS – Special Populations**).

**Geriatric patients (≥ 65 years of age):**

There are limited data on the use of SIGNIFOR in patients 65 years and older. Generally, dose selection for elderly patients should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

**Missed Dose**

If a dose of SIGNIFOR is missed, the next injection should be administered at the scheduled time. Doses should not be doubled to make up for a missed dose.

**Administration**

SIGNIFOR is to be administered subcutaneously by self-injection. Patients should receive instructions from the physician or a health care professional on how to inject SIGNIFOR subcutaneously.

Use of the same injection site for two consecutive injections is not recommended. Sites showing signs of inflammation or irritation should be avoided. Preferred injection sites for subcutaneous injections are the top of the thighs and the abdomen (excluding the navel and waistline).

**OVERDOSAGE**

Doses up to 2.1 mg twice a day have been used in healthy volunteers with adverse reactions including diarrhea and QT prolongation.

In the event of overdose, it is recommended that appropriate supportive treatment be initiated, as dictated by the patient's clinical status, until resolution of the symptoms. Electrocardiogram monitoring is recommended.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

**ACTION AND CLINICAL PHARMACOLOGY****Mechanism of Action**

Pasireotide is a novel cyclohexapeptide, injectable somatostatin analogue. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTR). Five human somatostatin receptor subtypes are known: SSTR 1, 2, 3, 4, and 5. These receptor subtypes are expressed in

different tissues under normal physiological conditions. Corticotroph tumour cells from Cushing's disease patients frequently over-express SSTR5 whereas the other receptor subtypes are often not expressed or are expressed at lower levels (SSTR1 and SSTR2). Pasireotide binds with high affinity to four of the five SSTRs: SSTR5 > SSTR2 > SSTR3 > SSTR1. Binding of pasireotide to corticotroph SSTR in ACTH producing adenomas results in inhibition of ACTH secretion.

### **Pharmacodynamics**

Somatostatin receptors are expressed in many tissues, especially in neuroendocrine tumours where hormones are excessively secreted including adrenocorticotrophic hormone (ACTH) in Cushing's disease.

*In vitro* studies have shown that corticotroph tumour cells from Cushing's disease patients display a high expression of SSTR5 whereas the other receptor subtypes are either not expressed or are expressed at lower levels. Pasireotide binds and activates the SSTR of the corticotrophs in ACTH producing adenomas resulting in inhibition of ACTH secretion. The high affinity of pasireotide for four of the five SSTRs, especially to SSTR5, provides the basis for pasireotide to be an effective treatment for Cushing's disease patients.

### **Cardiac Electrophysiology**

The effects of pasireotide (administered as SIGNIFOR s.c.) on cardiac electrophysiology were assessed in two dedicated ECG assessment studies (see **WARNINGS AND PRECAUTIONS - Cardiovascular** and **Monitoring and Laboratory Tests; ADVERSE REACTIONS; DRUG INTERACTIONS**).


ECG Study 1: In the first randomised, double-blind, placebo-controlled, crossover ECG assessment study, healthy volunteers (N=77) received treatment for 4 days with a suprathreshold dose of SIGNIFOR 1950 µg administered twice a day, followed by a 1950 µg morning dose on day 5. ECG assessments were performed at 10 time points on day 5. SIGNIFOR 1950 µg treatment was associated with statistically significant decreases in heart rate and prolongation of the Fridericia-corrected QT interval ( $QTcF=QT/RR^{0.33}$ ) at all timepoints on day 5. The maximum placebo-adjusted mean changes from baseline ( $\Delta\Delta QTcF$ ) occurred at 2 h post-dosing and were -12.6 bpm (90% CI -13.9, -11.3) for heart rate and 17.5 ms (90% CI 15.5, 19.4) for the QTcF interval. SIGNIFOR 1950 µg treatment was also associated with statistically significant increases in the PR interval, with a maximum placebo-adjusted mean change from baseline of 6.9 ms (90% CI 5.4, 8.5) at 4 h post-dosing.

ECG Study 2: In a second randomised, double-blind, placebo-controlled, crossover ECG assessment study in healthy volunteers (N=105), subjects received treatment for 4 days with a therapeutic dose of SIGNIFOR 600 µg twice a day and a suprathreshold dose of SIGNIFOR 1950 µg twice a day, followed by 600 µg and 1950 µg morning doses on day 5. ECG assessments were performed at 11 time points on day 5.

In both the 600 µg and 1950 µg treatment arms, SIGNIFOR was associated with statistically significant QTcF prolongation at all timepoints on day 5. The maximum placebo-adjusted mean change from baseline occurred at 2 h post-dosing in both treatment arms and was 11.8 ms (90%


CI 10.0, 13.5) in the 600 µg treatment arm and 14.0 ms (90% CI 12.3, 15.8) in the 1950 µg arm.

The mechanism for the observed QT prolongation is not known.




In both the 600 µg and 1950 µg treatment arms, SIGNIFOR was associated with statistically significant reductions in heart rate at all timepoints on day 5. The maximum placebo-adjusted mean change from baseline was -10.4 bpm (90% CI -11.5, -9.2) at 1 h post-dosing in the 600 µg treatment arm and -14.9 bpm (90% CI -16.1, -13.8) in the 1950 µg arm.

Time profile for placebo- and baseline-adjusted mean heart rate - Study B2125  
ECG set



Statistically significant prolongation of the PR interval occurred from 0.25 to 8 h post-dosing in the SIGNIFOR 600 µg arm and at all timepoints in the SIGNIFOR 1950 µg arm on day 5. The maximum placebo-adjusted mean change from baseline occurred at 2 h post-dosing in both treatment arms and was 6.1 ms (90% CI 4.6, 7.6) in the 600 µg arm and 9.9 ms (90% CI 8.4, 11.4) in the 1950 µg arm.

Time profile for placebo- and baseline-adjusted mean PR - Study B2125  
ECG sat



On the basis of population pharmacokinetic modelling, the median steady-state  $C_{max}$  of pasireotide in patients with Cushing’s disease is predicted to be 48 ng/mL for the 600 µg dose and 58 ng/mL for the 900 µg dose, both administered twice a day. In ECG Study 1, the median  $C_{max}$  for pasireotide 1950 µg twice a day in healthy volunteers was 64 ng/mL. In ECG Study 2, the median  $C_{max}$  values were 23 ng/mL for pasireotide 600 µg twice a day and 78 ng/mL for pasireotide 1950 µg twice a day.

### Pharmacokinetics

**Table 3 Summary of SIGNIFOR (twice a day dosing) Pharmacokinetic Parameters in Cushing’s Disease Patients**

| Dose (µg) | $C_{min,ss}$ (ng/mL)* | $C_{max,ss}$ (ng/mL)* | $T_{max,ss}$ (hr)** | $AUC_{0-8,ss}$ (hr*ng/mL) * |
|-----------|-----------------------|-----------------------|---------------------|-----------------------------|
| 600       | 4.9 ± 2.6             | 21.3 ± 6.9            | 2                   | 99.7 ± 33.8                 |

\*Data expressed as mean (SD) values from day 15;

\*\*Data expressed as median value from day 15.

**Absorption:** In healthy volunteers, pasireotide s.c. is rapidly absorbed and peak plasma concentration is reached within  $T_{max}$  0.25-0.5 hour.  $C_{max}$  and AUC are approximately dose-proportional following administration of single and multiple doses. In Cushing’s disease patients

following 600µg twice a day, s.c. dosing for 15 days, the steady-state was achieved within 5 days.

No studies have been conducted to evaluate the bioavailability of pasireotide in humans.

No clinical studies were performed to evaluate the effect of food on pasireotide administration.

**Distribution:** In healthy volunteers, pasireotide is widely distributed with large apparent volume of distribution ( $V_z/F >100$  L). Distribution between blood and plasma is concentration independent and shows that pasireotide is primarily located in the plasma (91%). Plasma protein binding is moderate (88%) and independent of concentration.

**Metabolism:** Pasireotide was shown to be highly metabolically stable. In healthy volunteers, pasireotide, in its unchanged form, is predominantly found in plasma, urine and feces.

**Excretion:** Pasireotide s.c. is eliminated mainly via hepatic clearance (biliary excretion) with a small contribution of the renal route. In a human ADME study with pasireotide s.c. administered as a single dose of 600 µg 55.9 ± 6.63% of the radioactivity dose was recovered over the first 10 days after pasireotide administration, including 48.3 ± 8.16% of the radioactivity in feces and 7.63 ± 2.03% in urine.

Pasireotide demonstrates low clearance (CL/F, ~ 7.6 litres/h for healthy volunteers and ~3.8 litres/h for Cushing's disease patients). Based on the accumulation ratios of AUC, the calculated effective half-life ( $t_{1/2, \text{eff}}$ ) in healthy volunteers was approximately 12 hours.

**Steady-State Pharmacokinetics, Linearity and Accumulation:** In Cushing's disease patients following 600 µg twice a day, s.c. dosing for 15 days, the steady-state was achieved within 5 days. In Cushing's disease patients, pasireotide demonstrates linear pharmacokinetics in a dose range from 0.3 to 1.2mg twice a day, based on  $C_{\text{min,ss}}$ , whereas the pasireotide pharmacokinetics was linear between 0.0025 to 1.5mg, in healthy volunteers. The accumulation (ratio of 1.9) of pasireotide was moderate in Cushing's disease patients.

### **Special Populations and Conditions**

**Pediatrics (< 18 years of age):** No studies have been performed in pediatric patients.

**Geriatrics (≥ 65 years of age):** Data on Cushing's disease patients older than 65 years are limited but do not suggest any clinically significant differences in safety and efficacy in relation to younger patients.

**Gender:** Population PK analyses of SIGNIFOR suggest that gender does not influence PK parameters.

**Race:** Population PK analyses of SIGNIFOR suggest that race does not influence PK parameters.



**Age:** Age has been found to be a covariate in the population PK analysis of Cushing's disease patients. Decreased total body clearance and increased PK exposures have been seen with increasing age. In the studied age range 18 to 73 years, the area under the curve at steady-state for one dosing interval of 12 hours ( $AUC_{ss}$ ) is predicted to range from 86% to 111% of that of the typical patient of 41 years. This variation is moderate and considered of minor significance considering the wide age range in which the effect was observed.

**Hepatic Impairment:** SIGNIFOR is contraindicated in patients with moderate or severe hepatic impairment (see **CONTRAINDICATIONS**). In a clinical study with single dose administration of pasireotide administered as Signifor s.c. in subjects with impaired hepatic function (Child-Pugh A, B and C), subjects with moderate and severe hepatic impairment (Child-Pugh B and C) showed significantly higher exposures than subjects with normal hepatic function. Upon correction for covariate effect (age, BMI and albumin)  $AUC_{inf}$  was increased by 60% and 79%,  $C_{max}$  increased by 67% and 69%, and CL/F decreased by 37% and 44%, respectively, in the moderate and severe hepatic impairment groups relative to the control group.

**Renal Impairment:** No dose adjustment is required in patients with impaired renal function. SIGNIFOR should be used with caution in patients with severe renal impairment.

In a clinical study with single dose administration of 900  $\mu$ g pasireotide as SIGNIFOR s.c. in subjects with impaired renal function, the degree of renal impairment did not have a significant impact on the pharmacokinetics of pasireotide. The  $AUC_{0-inf}$  decreased by 22% , 14% and 1% for mild, moderate and severe renally impaired subjects and increased by 25% in ESRD subjects compared to normal subjects adjusted for age, gender and weight as covariates. The  $C_{max}$  decreased by 28%, 23%, 19% and 10% for mild, moderate, severe renally impaired and ESRD subjects compared to normal subjects adjusted for age, gender and weight as covariates. However, increases in unbound pasireotide  $AUC_{inf,u}$  of 1.85, 2.41, 2.96 fold and  $C_{max,u}$  of 1.36, 2.00, 3.01 fold were observed in patients with moderate, severe renal impairment and ESRD. Grade 3 and Grade 4 increases in amylase, lipase and uric acid and grade 3 decreases in hemoglobin were also observed in subjects with severe renal impairment and ESRD. Hence, SIGNIFOR should be used with caution in patients with severe renal impairment and ESRD (see **WARNINGS AND PRECAUTIONS – Renal, WARNINGS AND PRECAUTIONS - Monitoring and laboratory tests, DOSAGE AND ADMINISTRATION**).

**Lean Body weight:** Lean body weight, has been found to be a covariate in the population PK analysis of Cushing's disease patients. In the studied lean body weight range 33 to 83 kg, the  $AUC_{ss}$  is predicted to range from 67% to 134% of that of the typical patient of 49 kg (The corresponding range of total body weight was 43.0 to 175 kg, with a median of 77.4 kg). This variation is considered as moderate and of minor clinical significance.

**Genetic polymorphism:** The effects of genetic polymorphisms on the pharmacokinetics of SIGNIFOR have not been established.

## **STORAGE AND STABILITY**

Store at room temperature (15°C – 25°C).

Store in original package (in order to protect from light).

SIGNIFOR (pasireotide injection) must be kept out of the reach and sight of children.

## **SPECIAL HANDLING INSTRUCTIONS**

The solution is supplied in a 1 mL one point-cut colorless hydrolytic class I (Ph. Eur., USP) glass ampoule.

To ensure proper administration of the drug, the patient should be instructed by a physician or other health care professional how to use the SIGNIFOR (pasireotide injection) ampoule. For instructions on the use of SIGNIFOR (pasireotide injection) ampoules, refer to the **CONSUMER INFORMATION** section.

Ampoules should be opened just prior to administration, and any unused portion discarded.

### **Special precautions for disposal**

Any unused product or waste material should be disposed of in accordance with local requirements.

### **Incompatibilities**

No compatibility data with other products have been generated. Pasireotide solution for injection is to be used without any dilution and must not to be mixed with other medicinal products.

## **DOSAGE FORMS, COMPOSITION AND PACKAGING**

SIGNIFOR (pasireotide injection) solution is available in three strengths. Each ampoule of 1 mL contains:

SIGNIFOR 0.3mg - 0.3 mg pasireotide (as diaspartate).

SIGNIFOR 0.6mg - 0.6 mg pasireotide (as diaspartate).

SIGNIFOR 0.9mg - 0.9 mg pasireotide (as diaspartate).

SIGNIFOR is available in packs containing 60 ampoules.

*Non-medicinal Ingredients;* Mannitol, sodium hydroxide, tartaric acid, water for injections.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION

#### Drug Substance

Proper name: Pasireotide diaspartate


Chemical name: (2-Aminoethyl)carbamic acid (2R,5S,8S,11S,14R,17S,19aS)-11-(4-aminobutyl)-5-benzyl-8-(4-benzyloxybenzyl)-14-(1H-indol-3-ylmethyl)-4,7,10,13,16,19-hexaoxo-17-phenyloctadecahydro-3a,6,9,12,15,18-hexaazacyclopentacyclooctadecen-2-yl ester, di[(S)-2-aminosuccinic acid] salt

Molecular formula and molecular mass:  $C_{58}H_{66}N_{10}O_9 \cdot 2 C_4H_7NO_4$

$$1047.206 + 266.205 = 1313.41$$

Salt/base ratio: 1.254

Structural formula:



Physicochemical properties: Pasireotide diaspartate, a novel cyclohexapeptide, is a somatostatin analogue. It is a white to slightly greyish powder (lyophilisate).

The aqueous ionization constants (pKa) of pasireotide were determined by potentiometric titration in water/dioxane in 0.15 M KCl at 25°C. The values are: pKa1 = 10.2, pKa2 = 9.1. At 25°C, the solubility of pasireotide is >100 mg/mL in water.

## CLINICAL TRIALS

### Study demographics and trial design

A phase III, multicenter, randomised study was conducted to evaluate the safety and efficacy of two dose levels of SIGNIFOR over a 6month treatment period in Cushing's disease patients with persistent or recurrent disease or *de novo* patients for whom surgery was not indicated or who refused surgery.

The study enrolled 162 patients with a baseline UFC  $>1.5 \times$  ULN who were randomised in a 1:1 ratio to receive a dose of either 0.6 mg s.c. twice a day or 0.9 mg s.c. twice a day of SIGNIFOR. After three months of treatment patients who had a mean 24-hour UFC  $\leq 2 \times$ ULN and below or equal to their baseline values continued blinded treatment at the randomised dose until month 6. Patients who did not meet these criteria were unblinded and the dose was increased by 0.3 mg twice a day. After the initial 6 months in the study, patients entered an additional 6-month open-label treatment period. The dosage can be reduced by 0.3mg s.c. twice a day at any time during the study for intolerability. The mean age of patients was approximately 40 years old with a predominance of female patients (77.8%). The majority of the patients had persistent or recurrent Cushing's disease (83.3%) despite pituitary surgery and few patients ( $\leq 5\%$ ) in either treatment group had received previous pituitary irradiation. The median exposure to the treatment was 10.4 months (0.03-37.8) with 68% of patients having at least 6 months.

Baseline characteristics were balanced between the two randomised dose groups, except for marked differences in the mean value of the baseline 24-hour UFC (1,156 nmoL/24hr for the 0.6 mg twice a day group and 782 nmoL/24hr for the 0.9 mg twice a day group); normal range 30 to 145 nmoL/24 hr).

The primary efficacy end-point was the proportion of patients in each arm who achieved normalization of mean 24-hour UFC levels (UFC  $\leq$  ULN) after 6 months of treatment and who did not have a dose increase (relative to randomised dose) during this period.

During the pivotal trial, 62% of patients with normal HbA1c ( $<6\%$ ) at baseline became either pre-diabetic or diabetic. HbA1c levels stabilized with the addition of antihyperglycemic treatment, but did not return to baseline values.

### Study results

Primary Endpoint: Normalization of UFC

At month 6, normalization of mean UFC levels was observed in 14.6% (95% CI 7.0% to 22.3%) and 26.3% (95% CI 16.6% to 35.9%) of patients randomised to pasireotide 0.6 mg twice a day and 0.9 mg twice a day, respectively. Over half of responders (55.6%) at month 6 were also responders at month 12.

A supportive efficacy analysis was conducted in which patients were further classified into the response category partial responder (UFC  $>1.0 \times$  ULN but with a reduction in UFC  $\geq 50\%$  compared to baseline). Up-titration at month 3 is allowed for 0.6mg dose group but not 0.9mg dose group. The total proportion of full or partial responders at month 6, constituted 33% and

37% (0.6 mg twice a day and 0.9 mg twice a day, respectively) of the randomised patients (Table 4). Patients uncontrolled at both Months 1 and 2 were likely (90%) to remain uncontrolled at Months 6 and 12.


**Table 4 Response rates at month 6 per randomised dose group**

| Response category | Pasireotide 0.6 mg b.i.d. (N=82) | Pasireotide 0.9 mg b.i.d.(N= 80) |
|-------------------|----------------------------------|----------------------------------|
|                   | n (%)                            | n (%)                            |
| Responder         | 12 (14.6%)                       | 21 (26.3%)                       |
| Partial responder | 15 (18.3%)                       | 9 (11.2%)                        |
| Non-responder     | 55 (67.1 %)                      | 50 (62.5%)                       |

Responder: fully controlled (UFC  $\leq 1.0 \times$  ULN) without up-titration at month 3; Partial responder: UFC  $>1.0 \times$  ULN but with a reduction in UFC  $\geq 50\%$  compared to baseline. Up-titration at month 3 is allowed for 0.6mg dose group but not 0.9mg dose group; non-responder: neither a responder nor a partial responder.

In both dose groups, SIGNIFOR resulted in a decrease in the mean UFC after 1 month of treatment which was maintained over time (Figure 1). Dose decreases and increases appeared to have minimal effect on UFC response.

**Figure 1 Mean ( $\pm$ SE) Urinary Free Cortisol (nmol/24h) at time points up to Month 12 by randomised dose group**



Note: The reference line is the upper limit normal for UFC, which is 145 nmol/24h.  $\pm$ Standard errors are displayed.

Decreases were also demonstrated by the overall percentage of change in the mean UFC levels at month 6 and 12 as compared to baseline values (Table 5).

**Table 5 Percentage change in mean UFC levels per randomised dose group at Month 6 and month 12 compared to baseline values**

|   |          | Pasireotide 0.6 mg b.i.d. | Pasireotide 0.9 mg b.i.d. |
|---|----------|---------------------------|---------------------------|
|   |          | % change (n)              | % change (n)              |
| Mean change in UFC<br>(% from baseline) | Month 6  | -27.5* (52)               | -48.4 (51)                |
|   | Month 12 | -41.3 (37)                | -54.5 (35)                |

\* Includes one patient with significant outlying results who had a percent change from baseline of +542.2%.

## DETAILED PHARMACOLOGY

### Nonclinical Pharmacology

#### *In vitro pharmacology*

Corticotroph tumour cells from Cushing's disease patients express high levels of SSTR5. Other receptor subtypes (SSTR 1-4) are either not expressed or are expressed at lower levels. Pasireotide is a somatostatin analogue with high binding affinity and high functional activity for somatostatin receptor subtypes SSTR 1, 2, 3 and 5. The high affinity of pasireotide for four of the five SSTRs, especially to SSTR5, provides the basis for pasireotide's mechanism of action. In a primary mouse ACTH secreting pituitary cell line, pasireotide inhibited the release of ACTH with high potency ( $IC_{50}$  0.2 nmol/L). Similarly, pasireotide inhibited release of ACTH secretion from human corticotroph adenoma cells.

#### *In vivo pharmacology*

In vivo studies showed a strong inhibitory effect of pasireotide on ACTH and corticosterone secretion in rats pre-treated with corticotropin-releasing hormone.

### Nonclinical Pharmacokinetics

Pasireotide is well absorbed after s.c. dosing in all species tested with complete bioavailability. The plasma protein binding is moderate across species with the lowest binding in human (88%); therefore a substantial change in drug kinetics due to protein binding changes is not expected. Pasireotide and/or its metabolites in tissues were eliminated slowly and were mainly distributed to the adrenal cortex, kidney cortex, bone marrow, blood vessel wall, lymph nodes, spleen, and liver while showing minimal brain penetration and no specific retention in melanin-rich tissues (uveal tract and skin). Pasireotide and/or its metabolites showed some distribution to the fetus in rats and rabbits. The transfer of pasireotide-related radioactivity into milk was observed in rats.

### Clinical Pharmacology

#### **Clinical Pharmacokinetics (PK)**

In healthy volunteers, following a single s.c. injection between 2.5 - 1500 µg, pasireotide pharmacokinetics demonstrated fast absorption, extensive distribution, low clearance, and long half-life. The PK exposures ( $C_{max}$  and  $AUC_{inf}$ ) were approximately dose-proportional for single

(2.5 – 1500 µg) and multiple doses (50- 600 µg). The drug was rapidly absorbed with a median  $T_{max}$  of 0.25-0.5 hr post dose. The disposition phase of the mean plasma concentration-versus-time profiles of pasireotide appeared to be tri-exponential for doses of 600-1500 µg. The apparent effective half-life ( $t_{1/2}$ ) was estimated to be ~12 hours. Pasireotide is primarily distributed in the plasma (91%) with a large apparent volume of distribution ( $V_z/F$ ) >100 L. Pasireotide is metabolically stable and is found in its unchanged form in plasma, urine and feces. Pasireotide is eliminated mainly via hepatic clearance (biliary excretion) with a small contribution from the renal route. The clearance (CL/F) of pasireotide in healthy volunteers and Cushing's disease patients is ~ 7.6 liters/h and ~3.8 litres/h, respectively. Following 50- 600 µg q.d. dosing of pasireotide s.c. in healthy volunteers, the steady-state was achieved within 3 days. The accumulation to steady-state was found to be moderate (approximately 20-40%) (see **ACTION AND CLINICAL PHARMACOLOGY**).

## **TOXICOLOGY**

### **Safety pharmacology**

The cardiovascular safety of pasireotide was evaluated using *in vitro* methods (hERG assay, Purkinje fiber assay, effect of pasireotide on potassium channel currents, effect of pasireotide on sodium and calcium channel currents) and in an *in vivo* conscious monkey telemetry study (single s.c. doses of 0.4, 0.8 and 1.6 mg/kg). *In vitro*, a statistically significant, concentration-dependent hERG current block was observed at 13 and 39 µg/mL (8.2% and 16.8% inhibition, respectively). These concentrations are 448 and 1345 times human  $C_{max}$  at 900 µg bid, respectively. There were no other findings. *In vivo*, a NOAEL of 1.6 mg/kg was obtained.

The effect of pasireotide on respiratory function and neurobehaviour was assessed in rats (single s.c. doses of 0.8, 1.6 and 4.0 mg/kg) and mice (single s.c. doses of 0.4, 1.2, 4.0 and 12 mg/kg), respectively. Toxicologically significant effects were not observed.

### **Single dose toxicity**

The acute toxicity of pasireotide was assessed in rats and mice at 15 and 30 mg/kg by the s.c. route. Lethalities were not observed.

### **Repeated dose toxicity**

#### **Rats**

The pivotal rodent repeat-dose toxicity study was conducted in male and female rats. Animals were administered pasireotide by s.c. injection once daily at 0.0008, 0.024, 0.08 and 0.24 mg/kg/day for 26 weeks. When compared with human AUC values, these dose levels provide an exposure margin of 0.07, 0.24 (0.33 and 0.15 for males and females, respectively), 0.49, 1.92, respectively. The NOAEL was considered to be 0.024 mg/kg/day based on histological alterations in the pituitary (males) and the genital tract (females).

All pasireotide-mediated effects were considered to be a result of the drug's pharmacology and all changes demonstrated reversibility following a drug-free period. Decreased body weight was observed in males (from 0.008 mg/kg) and females (0.24 mg/kg). In males, decreased pituitary weight and decreased cytoplasmic mass of acidophile cells/somatotrophs was observed at doses >0.024 mg/kg. In females, alterations in the genital tract (decreased number of corpora lutea,

vaginal mucosal hyperplasia or hypertrophy of mucification, vaginal hypertrophy) consistent with prolongation of the estrous cycle were observed at doses  $\geq 0.08$  mg/kg.

Inhibitory effects on lymphoid and hematopoietic organs were observed and included decrease thymus weight and cellularity as well as decreased hematopoietic activity of the spleen and bone marrow. A lack of new bone formation beneath the epiphyseal plate of the tibia and femur was observed. Serum biochemistry changes (increased ALT, decreased albumin) and decreased liver weight suggested possible effects on the liver at high dose levels, possibly as a secondary result to the decrease in IGF-1. Changes in coagulation parameters (increased PT and APTT) noted in females are likely related to the pharmacologic effect of pasireotide, probably through modification of the liver production of coagulating factors regulated by GH.

### **Monkeys**

The pivotal non-rodent repeat-dose toxicity study was conducted in male and female monkeys. Animals were administered pasireotide at 0.4, 1.6, and 3.2 mg/kg/day for 39 weeks. When compared with human AUC values, these dose levels provide an exposure margin of 12.2, 39.0 and 96.1 for males, and 13.3, 54.7 and 102.6 for females. The NOAEL was considered to be 1.6 mg/kg/day based on histological alterations in the pituitary (increased acidophilia in the pars distalis), thyroid (small follicles), large intestine (distension with firm fecal material) and injection site reactions.

All pasireotide-mediated effects were considered to be a result of the drug's pharmacology and all changes demonstrated reversibility following a drug-free period.

### **Genotoxicity**

Pasireotide did not exhibit mutagenic or clastogenic potential in a battery of assays including the Ames test, human peripheral lymphocyte chromosome aberration test, or the *in vivo* rat micronucleus test.

### **Carcinogenicity**

The carcinogenic potential of pasireotide was assessed by the s.c. route in the 26-week transgenic RasH2 mouse model (dose levels: 0, 0.5, 1.0, 2.5 mg/kg/day) and the 2-year rat bioassay (dose levels: 0, 0.01, 0.05, 0.3 mg/kg/day). Pasireotide was not carcinogenic in either model.

### **Reproductive and Developmental Toxicity**

Fertility and early embryonic development was evaluated in rats. Pasireotide was administered by s.c. injection at 0.1, 1.0 and 10 mg/kg/day prior to mating, during mating and through gestation day (GD) 6. Reproductive effects were observed in females only and included prolonged estrus cycles/acyclicity at doses  $\geq 1.0$  mg/kg and decreased numbers of corpora lutea, implantation sites, and/or viable fetuses at all doses. A NOAEL for female fertility was not established ( $<0.1$  mg/kg/day).

Embryo-fetal development was evaluated in rats and rabbits. In rats, pasireotide was administered by s.c. injection at 1, 5 and 10 mg/kg/day from GD 6-17. At 10 mg/kg, and in the presence of maternal toxicity and mortality, effects on the F<sub>1</sub> generation were noted and consisted of increased early/total resorptions, decreased fetal weights, and mal-rotated limbs. The fetal NOAEL was 5 mg/kg. Pasireotide was not teratogenic in the rat.



In rabbits, pasireotide was administered by s.c. injection at 0.05, 1.0 and 5.0 mg/kg/day from GD 7-20. Maternal toxicity was observed from 1.0 mg/kg and mortality occurred at 5.0 mg/kg. Reproductive and fetal effects (increased early and/or total resorptions, decreased fetal weights) were noted in the presence of maternal toxicity at doses  $\geq 1$  mg/kg. At 5 mg/kg, abortions and a decreased number of viable fetuses were seen. Increased skeletal variations noted at 5.0 mg/kg were considered secondary to the reduced fetal weights. The maternal and fetal NOAEL were 0.05 mg/kg. Pasireotide was not teratogenic in the rabbit.

Pre- and post-natal development was evaluated in rats. Pasireotide was administered by s.c. injection at 2, 5 and 10 mg/kg/day to F<sub>0</sub> generation dams from GD 6 to day 21, 22 or 23 *post partum*. Maternal toxicity was observed at all doses and drug-related mortality was noted at 5 mg/kg. Maternal performance was unaffected by administration of pasireotide (no change in gestation index, length of gestation, numbers of live, dead pups, number of implantation scars, sex ratio and the live birth index). Lower F<sub>1</sub> body weights were seen at all doses. Secondary to the lower pup weights, the mean day of pinna unfolding was slightly increased in all dose groups. Post weaning, body weight gains were comparable for all groups demonstrating reversibility. There was no effect on visual function, physical development, behavioural performance, macroscopic findings, parental performance or uterine findings for the F<sub>1</sub> generation adults.

#### **Antigenicity**

Antigenicity was not evaluated with the s.c. formulation. Using pasireotide LAR in a rat i.m. study, anti-pasireotide antibodies were detected in 26/59 treated animals. The antibodies were considered non-neutralizing as pharmacologic effects and drug levels were sustained.

#### **Immunotoxicity**

The immunotoxic potential of pasireotide was evaluated in a 4-week rat s.c. immunotoxicity study (dose levels: 0.08, 0.24 and 0.8 mg/kg/day). Pasireotide exhibits low immunotoxic potential. Although a slight decrease in lymphocytes counts was observed in males at 0.24 and 0.8 mg/kg/day (total lymphocyte counts and absolute counts of Total T lymphocytes, Helper T lymphocytes, Cytotoxic T lymphocytes, natural killer lymphocytes and B lymphocytes), there were no toxicologically-relevant pasireotide effects on immune function (anti-KLH IgM, anti-KLH IgG responses unaffected by pasireotide treatment).

#### **Phototoxicity**

In the absorption spectrum of pasireotide, a significant peak was found at around 360 nm. An *in vitro* phototoxicity assay was performed. Pasireotide did not exhibit phototoxic potential.

## REFERENCES

- 1) Colao, A, Petersenn, S, Newell-Price, J et al. (2012) A 12-month phase 3 study of pasireotide in Cushing's disease. *N Engl J Med*; 366:914-24.
- 2) Rasmussen E, Eriksson B, Öberg K, et al (1998) Selective effects of somatostatin analogs on human drug-metabolizing enzymes. *Clin Pharm and therapeutics*; 64(2):150-9.
- 3) Flogstad AK, Halse J, Grass P, et al (1994) A comparison of octreotide, bromocriptine, or a combination of both drugs in Acromegaly. *J Clin Endo and Metabol*; 79(2):461-5.
- 4) Schmid HA, Schoeffter P (2004) Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors. *Neuroendocrinology*. 80(1):47-50.
- 5) Van der Hoek J, Waaijers M, van Koetsveld PM, et al (2005) Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. *Am J Physiol Endo and Metabol*; 289(2):E278-87.
- 6) Van der Hoek J, Lamberts SWJ, Hofland LJ (2004) The role of somatostatin analogs in Cushing's disease. *Pituitary*. Vol. 7(4): 257-264.
- 7) Hofland LJ, van der Hoek J, Feelders R, et al (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. *European Journal of Endocrinology*. Vol. 152(4). 645-654.
- 8) Webb SM, Badia X, Barahona MJ et al (2008) Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. *Eur J Endocrinol*; 158(5):623-30.

**PART III: CONSUMER INFORMATION****PrSIGNIFOR®  
(Pasireotide injection)**

This leaflet is part III of a three-part "Product Monograph" published when SIGNIFOR® was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about SIGNIFOR. Contact your doctor or pharmacist if you have any questions about the drug.

**ABOUT THIS MEDICATION****What the medication is:**

SIGNIFOR 0.3 mg, 0.6 mg and 0.9 mg solution for injection contains the active substance pasireotide, which is a synthetic compound derived from somatostatin.

**What the medication is used for:**

SIGNIFOR (pasireotide) is used in adults. It is a medicine to treat a disease called Cushing's. It is used when surgery is not an option or has not produced the required results. Cushing's disease is a condition caused by an enlargement of a part of the gland called the pituitary at the base of the brain, a so-called pituitary adenoma. This adenoma leads the body to make large amounts of a hormone called adrenocorticotropic hormone (ACTH).

SIGNIFOR should only be prescribed and supervised by a qualified doctor. To receive SIGNIFOR, you must be enrolled in the Access Program for SIGNIFOR.

**What it does:**

SIGNIFOR is a medicine containing a novel synthetic substance that mimics the action of somatostatin, a substance normally found in the human body, which can block the production of certain hormones, such as ACTH.

**When it should not be used:**

- If you are allergic to pasireotide or to any other ingredient in the medication or its container
- If you have moderate or severe liver problems
- If you have uncontrolled diabetes
- If you are pregnant
- If you are a woman of childbearing potential and not using contraception (birth control)
- If you are breastfeeding
- If you have heart problems

**What the medicinal ingredient is:**

Pasireotide diaspertate.

**What the nonmedicinal ingredients are:**

Mannitol, sodium hydroxide, tartaric acid, and water for injections.

**What dosage forms it comes in:**

SIGNIFOR is a solution supplied in an ampoule containing 1 mL of a clear, colourless solution.

Each ampoule contains 0.3 mg or 0.6 mg or 0.9 mg pasireotide (as pasireotide diaspertate).

SIGNIFOR is available in packs containing 60 ampoules.

**WARNINGS AND PRECAUTIONS****Serious Warnings and Precautions**

Serious side effects include:

- Liver problems
- Heart problems (i.e. slow or irregular heart beat)
- Changes in blood glucose levels

**BEFORE you use SIGNIFOR talk to your doctor or pharmacist if:**

- You have problems with your blood sugar levels, either too high (diabetes) or too low (hypoglycaemia)
- You have problems with your liver
- You have severe kidney problems
- You have heart problems. This includes an abnormal heart rate or rhythm. This can also include problems with the electrical system of your heart called QT prolongation
- Take medicines to control your heart beat (antiarrhythmics) or medicines that may have an unwanted effect on the function of the heart beat (QT prolongation)
- You have a history of fainting spells
- You have low levels of pituitary hormones
- You have low levels of potassium or magnesium in your blood
- You have conditions such as vomiting, diarrhea, dehydration
- You have gallstones
- You are pregnant, may be pregnant or thinking or becoming pregnant. Your doctor will discuss whether you can become pregnant or not.
- You are breastfeeding. It is not known if SIGNIFOR passes into breast milk
- You take medicines to control your blood pressure (such as beta-blockers or calcium channel blockers)
- You take medicines to control electrolytes (potassium, magnesium) balance in your body
- You take medicines that affect how your blood clots

Your doctor may wish to check your blood sugar levels. You may need to start taking medicines to control your blood sugar levels or your doctor may adjust the medicines you are now taking to control your blood sugar levels.

**Before your doctor prescribes SIGNIFOR, they should do tests including:**

- Blood tests
- Liver tests

- Electrocardiogram, to measure the electrical activity of the heart
- Gallbladder ultrasound

These tests should be repeated during treatment.

Your doctor may wish to check your gallbladder, liver enzymes and pituitary hormones on a regular basis.

### During your treatment with SIGNIFOR

Tell your doctor straight away if:

- You are feeling very weak
- You lose weight
- You have nausea or vomiting
- You have low blood pressure

### Children and adolescents (under 18 years old)

SIGNIFOR is not to be used in children or adolescents.

To prevent pregnancy, female patients of childbearing potential should use adequate birth control.

**Driving and Using Machines:** Before you perform tasks which may require special attention, wait until you know how you respond to SIGNIFOR as fatigue or headache can occur.

## INTERACTIONS WITH THIS MEDICATION

The following list includes some, but not all, of the drugs that may increase the risk of heart rhythm problems while receiving SIGNIFOR. You should check with your doctor or pharmacist before taking any other medication with SIGNIFOR.

### Drugs that may interact with SIGNIFOR include:

- Anti-arrhythmics used to treat irregular heart beat such as amiodarone, disopyramide, procainamide, quinidine, sotalol, ibutilide, dronedarone, flecainide, propafenone
- Medicines that may have an unwanted effect on the function of the heart (QT prolongation) such as:
  - antipsychotics (e.g., haloperidol, pimozide, droperidol, ziprasidone, chlorpromazine)
  - antidepressants (e.g., imipramine, citalopram, amitriptyline, maprotiline, venlafaxine)
  - methadone
  - antibiotics (e.g., clarithromycin, moxifloxacin, erythromycin, azithromycin, tacrolimus, levofloxacin, ciprofloxacin)
  - antimalarials (e.g., chloroquine, quinine)
  - antifungals (e.g., ketoconazole, fluconazole, voriconazole)
  - dopamine receptor antagonists (e.g. domperidone)
  - antiemetics (e.g., intravenous ondansetron)
  - cancer drugs (e.g., sunitinib, nilotinib, vandetanib, lapatinib, vorinostat)
- Asthma drugs (e.g., formoterol, salmeterol)
- Diuretics (water pills)
- Laxatives and enemas
- Amphotericin B
- High dose corticosteroids
- Medicines that decrease heart rate and prolong the PR interval:

- antihypertensives (e.g., atenolol, diltiazem, verapamil, clonidine)
- drugs to treat heart failure (e.g., digoxin)
- drugs to treat multiple sclerosis (e.g., fingolimod)
- drugs to treat HIV infection (e.g., atazanavir)
- Certain other medicines, such as cyclosporine, bromocriptine
- Medicines that work to prevent blood clots (anticoagulants)
- Antidiabetic drugs including insulin and oral medicines

This list includes some, but not all, of the drugs that may increase the risk of side effects while receiving SIGNIFOR. Tell your doctor or pharmacist if you are taking these or any other medicines even those not prescribed (including any over the counter drugs, vitamins, or herbal medicines).

## PROPER USE OF THIS MEDICATION

### Usual dose:

The recommended dose of SIGNIFOR is 0.6 mg injected under your skin (subcutaneous) two times a day (approximately every 12 hours). Using SIGNIFOR at the same time each day will help you remember when to use your medicine.

Your doctor will monitor how you respond to the treatment with SIGNIFOR and may ask you to change to a higher or lower dose.

### How long to take SIGNIFOR

Your doctor will regularly check your condition to see if the treatment is working. You will need to take SIGNIFOR for as long as your doctor tells you. This is a long-term treatment, possibly lasting for years. If you stop your treatment your symptoms may come back.

### Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

### Missed Dose:

Do not use a double dose of SIGNIFOR to make up for a forgotten dose. If you forgot to administer a dose of SIGNIFOR simply take your next injection at the scheduled time.

### Instructions for use of SIGNIFOR

Your health care practitioner will have instructed you on how to use SIGNIFOR ampoules. However, before using the ampoule, please read the following information carefully. If you are not sure about how to give the injection or you have any questions, please ask your doctor, nurse or pharmacist for help.

The injection can be prepared using either two different needles to draw up and inject the solution or one short fine injection needle for both steps. Based on the local clinical practice, your doctor or nurse will tell you which method to use. Please follow their instructions.

Store the SIGNIFOR ampoules according to the storage condition listed on the box.

**Important Safety Information**

**Caution: Keep the ampoule out of the reach of children**

**What you need, to give yourself a subcutaneous injection:**

1. One SIGNIFOR ampoule
2. Alcohol wipes or similar
3. One sterile syringe
4. One long thick blunt sterile needle for drawing up the solution (your doctor or nurse will tell you if this is needed)
5. One short fine sterile needle
6. A sharps container or other rigid closed disposal container

**The Injection Site**

The injection site is the place on your body where you are going to give yourself the injections. SIGNIFOR is intended for subcutaneous use. This means that it is injected through a short needle into the fatty tissue just under the skin. The thighs or the abdomen are good areas for subcutaneous injection. Avoid soreness and skin irritation by choosing a different site from the previous one for each injection. You should also avoid injections at sites that are sore or where the skin is irritated.

**Getting started**

When you are ready to give yourself the injection, carefully follow the steps below:

- Wash your hands thoroughly with soap and water.
- Always use new disposable needles and syringes every time you give yourself an injection.
- Use syringes and needles only once. **Never** share needles and syringes with someone else.
- Take the ampoule out of the box.
- Carefully inspect the ampoule. **DO NOT USE** if it is broken or if the liquid looks cloudy or contains particles. In all these cases, return the entire product pack to the pharmacy.

Ampoules should be opened just prior to administration, and any unused portion discarded.






**Check the expiry date and the dose:**





Check the expiry date (EXP) which is stated on the ampoule label and check that it is the dose your doctor has prescribed for you.

**DO NOT USE if the product has expired or if the dose is not the one you have been prescribed. In both cases, return the entire product pack to the pharmacy.**

**How to inject SIGNIFOR**

|  |   |
|--|---|
|  | <p><b>Step 1:</b> SIGNIFOR solution for injection is filled in a break-off ampoule. The colored dot on the top part marks the position of the breaking cut on the neck of the ampoule. Tap the ampoule with your finger in order to make sure there is no liquid in the top part when you open the ampoule.</p> |
|--|---|

|  |  |
|--|--|
|    | <p>The solution should be free of visible particles, clear and colorless. Do not use SIGNIFOR if the solution is not clear or contains particles.</p>  |
|    | <p><b>Step 2:</b> Recommended procedure: hold the ampoule in an upright position with the colored dot facing away from you. Hold the base of the ampoule in one hand. Keeping your thumbs together above and below the neck, break off the top of the ampoule at the breaking cut. Once open, put the ampoule upright on a clean, flat surface.</p>  |
|   | <p><b>Step 3:</b> Take the sterile syringe and attach the needle to it. If you have been told to use two needles, you should use the long thick blunt one for this step.</p> <p>Before you proceed to step 4, clean the injection site with an alcohol wipe.</p>   |
|  | <p><b>Step 4:</b> Remove the cover from the needle. Put the needle into the ampoule and pull the plunger to draw the entire contents of the ampoule into the syringe. If you have been told to use two needles, you should now replace the long needle with the short one.</p>   |
|  | <p><b>Step 5:</b> Hold the syringe in one hand between two fingers with your thumb at the bottom of the plunger. Tap the syringe with your fingers to get rid of air bubbles. Make sure there is no air bubble in the syringe by pressing the plunger until the first drop appears on the tip of the needle.</p> <p>Do not let the needle touch anything. You are now ready to inject.</p> |
|  | <p><b>Step 6:</b> Gently pinch the skin at the injection site and, holding the needle at an angle of approximately 45 degrees (as</p>  |

|  |  |
|--|--|
|    | <p>shown in the picture) insert it into the injection site.</p> <p>Pull slightly on the plunger to check that a blood vessel has not been punctured. If you see blood in the syringe, first remove the needle from the skin, then replace the short needle with a new one and insert it into a different injection site.</p> |
|    | <p><b>Step 7:</b> Always keeping your skin pinched, slowly press down the plunger as far as it will go <u>until all the solution is injected</u>. Keep the plunger pressed down and hold the syringe in place for 5 seconds.</p>   |
|    | <p><b>Step 8:</b> Slowly release the skin fold and gently pull the needle out. Put the cover back on the needle.</p>   |
|  | <p><b>Step 9:</b> Dispose of the used syringe immediately in a sharps container or other rigid closed disposal container. Any unused product or waste material should be disposed of in accordance with local requirements.</p>  |

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

**Side effects may include:**

- Diarrhea, nausea, abdominal pain, vomiting, loss of appetite, constipation, indigestion, bloating, weight loss, altered taste, flatulence, dry mouth
- Fatigue, weakness, discomfort, muscle and joint pain, drowsiness, fainting, dizziness, tremor
- Local pain, redness, irritation, itching, rash, hives and/or swelling at the injection site
- Dry, itchy, sweaty, bruised skin
- Headache
- Hair loss
- Blurred vision
- Flushing

**If any of these affects you severely or does not go away, tell your doctor.**

SIGNIFOR can cause abnormal blood test results. Your doctor will decide when to perform blood tests and will interpret the results.

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

| Symptom / effect   |  | Talk with your doctor or pharmacist |              | Stop taking drug and call your doctor or pharmacist |
|--------------------|--|-------------------------------------|--------------|---|
|                    |  | Only if severe                      | In all cases |   |
| <b>Very Common</b> | <p><b>High level of sugar in the blood</b><br/>excessive thirst, high urine output, increased appetite with weight loss, tiredness</p>               |                                     |              | √   |
|                    | <p><b>Gallstones</b><br/>- right-sided chest pain below rib cage<br/>-pain in the back right shoulder blade<br/>- nausea, vomiting, gas, burping</p> |                                     |              | √   |
| <b>Common</b>      | <p><b>Low cortisol levels</b><br/>extreme weakness, weight loss, nausea, vomiting, low blood pressure</p>  |                                     |              | √   |
|                    | <p><b>Adrenal Insufficiency</b><br/>Fatigue, muscle weakness, loss of appetite, weight loss, abdominal pain</p>                                      |                                     | √            |   |
|                    | <p><b>Heartbeat disturbance</b><br/>weakness, tiredness, shortness of breath, lightheadedness, fainting, dizziness, palpitations, seizures</p>       |                                     |              | √   |
|                    | <p><b>Prolonged QT interval</b><br/>dizziness, palpitations, fainting, seizures</p>  |                                     |              | √   |

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

| Symptom / effect   | Talk with your doctor or pharmacist |              | Stop taking drug and call your doctor or pharmacist |
|--|-------------------------------------|--------------|---|
|  | Only if severe                      | In all cases |   |
| <b>Low blood pressure</b><br>Dizziness, fainting, lightheadedness  |                                     | √            |   |
| <b>High blood pressure</b><br>headache   | √                                   |              |   |
| <b>Liver disorder</b><br>nausea, vomiting, loss of appetite combined with itching, yellowing of the skin or eyes, dark urine, abdominal pain                                       |                                     |              | √   |
| <b>Pancreatic disorder</b><br>acute or chronic abdominal pain (frequently radiating to the back), indigestion, nausea and vomiting, diarrhea, swollen and tender abdomen, bloating |                                     |              | √   |
| <b>Coagulation disorder</b><br>severe bruising or unusual bleeding from the skin or other areas  |                                     |              | √   |
| <b>Uncommon</b>  |                                     |              |   |
| <b>Low level of red blood cells:</b><br>tiredness, fatigue, pale skin  |                                     |              | √   |

**HOW TO STORE IT**

- Store between 15-25°C.
- Keep this medicine out of the reach and sight of children.
- Store in the original package in order to protect from light.

Medicines should not be disposed via household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

**REPORTING SUSPECTED SIDE EFFECTS**

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: **Canada Vigilance Program**  
**Health Canada**  
**Postal Locator 0701E**  
**Ottawa, Ontario**  
**K1A 0K9**

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect).

*NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.*

**MORE INFORMATION**

This document plus the full product monograph, prepared for health professionals can be found at: [www.novartis.ca](http://www.novartis.ca) or by contacting the sponsor, Novartis Pharmaceuticals Canada Inc., at: 1-800-363-8883

<sup>Pr</sup> SIGNIFOR is a registered trademark  
This leaflet was prepared by:  
Novartis Pharmaceuticals Canada Inc.  
Dorval, Quebec  
H9S 1A9

Last revised: March 21, 2017

*This is not a complete list of side effects. For any unexpected effects while taking SIGNIFOR, contact your doctor or pharmacist.*